Cleared Traditional

NeuTrace EP Mapping System v.2.1 (K233160) - FDA 510(k) Clearance

Class II Cardiovascular device cleared through predicate-based substantial equivalence - typically does not require clinical trials.

K233160 · Anumana, Inc. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Nov 2023
Decision
59d
Days
Class 2
Risk

K233160 is an FDA 510(k) clearance for the NeuTrace EP Mapping System v.2.1. Classified as Computer, Diagnostic, Programmable (product code DQK), Class II - Special Controls.

Submitted by Anumana, Inc. (Cambridge, US). The FDA issued a Cleared decision on November 25, 2023 after a review of 59 days - a notably fast clearance cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1425 - the FDA cardiovascular device oversight framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Anumana, Inc. devices

Submission Details

510(k) Number K233160 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 27, 2023
Decision Date November 25, 2023
Days to Decision 59 days
Submission Type Traditional
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
66d faster than avg
Panel avg: 125d · This submission: 59d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DQK Computer, Diagnostic, Programmable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQK Computer, Diagnostic, Programmable

All 183
Devices cleared under the same product code (DQK) and FDA review panel - the closest regulatory comparables to K233160.
LumiGuide Wire
K233853 · Philips Medical Systems Nederland B.V. · Mar 2024
Affera Mapping System (AFR-00003)
K233943 · Medtronic, Inc. · Mar 2024
CASE V7.0 Cardiac Testing System and CardioSoft V7.0 Cardiac Testing System
K231870 · Ge Medical Systems Information Technologies, Inc. · Dec 2023
HemoSphere Alta Advanced Monitoring Platform
K232294 · Edwards Lifesciences, LLC · Oct 2023
Volta AF-Xplorer
K232616 · Volta Medical · Sep 2023
AVVIGO'+ Multi-Modality Guidance System
K230884 · Boston Scientific Corporation · Sep 2023